Conventus Orthopaedics, Inc., an orthopedic company focused on lower extremities, extremity trauma, and wound care solutions, has signed an agreement to acquire Flower Orthopedics, a provider of sterile-packaged foot and ankle implants, allografts, and diabetic wound care solutions.
Conventus Agrees to Acquire Flower Orthopedics
1 min read Premium comments
#conventusorthopaedics#flowerorthopedics
Minneapolis, Minnesota-based Conventus is best known for its nitinol CAGETM technology that is used to treat proximal humerus and distal radius fractures. The CAGE technology offers increased stability and reduced complications when compared to traditional plating methods. Conventus lower extremity CAGE implants are currently in development.
Horsham, Pennsylvania-based Flower Orthopedics provides Ready-for-SurgeryTM foot and ankle surgical solutions. Its portfolio of products are intended to decrease the number of surgical steps, which reduces costs without compromising clinical outcomes.
This acquisition follows Conventus’ recent acquisition of an intramedullary distal fibula system from Surgical Frontiers.
Conventus CEO Rick Epstein said of the acquisition, “Flower is an excellent strategic fit with Conventus. With the backing of our lead investor, Deerfield Management, Flower represents the next step of our aggressive transformation into a formidable orthopedic supplier. We will continue to expand our distribution channel and enhance our portfolio through product development and acquisitions that address unmet surgeon and institution needs.”
Flower Ortho’s Chairman George Jenkins stated, “I along with our shareholders are convinced that Conventus and Deerfield are ideal partners to further accelerate Flower’s growth by expanding our distribution channel and accelerating product development. We are all excited to become Conventus shareholders.”
Andrew ElBardissi, partner at Conventus’ lead investor Deerfield Management, stated, “We are excited about the progress that Conventus has made over the past year. With the acquisition of Flower Orthopedics, we believe the company is positioned to be a leader in the development of innovative orthopedic technologies. We look forward to supporting the company’s continued growth.”
The acquisition is set to close following the completion of all closing terms. The terms of the deal were not disclosed.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.